California Green Chemistry Initiative - June 29, 2009
9:00 - 11:00 am | 1000 Marsh Rd., Menlo Park CA 94025

Speakers
Kathleen Patterson, Partner, Orrick Herrington & Sutcliffe LLP bio
Kathryn Edwards, Partner, Orrick Herrington & Sutcliffe LLP bio

In furtherance of California's Green Chemistry Initiative, the legislature enacted two statutes late last year which authorized California state government to develop an alternatives analysis framework to stimulate the rapid acceleration of replacement of harmful chemicals and ingredients with safer alternatives in consumer products sold in California. The statutory definition of "consumer product" is very broad: "a product or part of the product that is used, brought, or leased for use by a person for any purposes." The only products explicitly excluded from the definition are drugs and medical devices, dental restorative materials, food, packaging for drugs, devices, dental restorative materials and food, pesticides, and mercury containing lights.

California's Department of Toxic Substances Control ("DTSC") is currently drafting the implementing regulations. The regulations will establish a process to identify and prioritize chemicals of concern (CoCs); establish a process to assess safer alternatives; and establish a range of regulatory responses that DTSC may take following the safer alternatives analysis.

DTSC intends to have the regulations ready for public comment by September 2009, with the goal of having the regulations in place by the end of the year. The regulations will undoubtedly have a significant impact on most industries. Apart from the burden on resources imposed by undertaking alternatives assessments, the regulations may necessitate changes in R&D; strategies, supply-chain relationships, and the way in which companies manage their intellectual property.

Upcoming BioCenter Events

Meet With … Physic Ventures
June 30, 2009 | 9:00 am - 4:00 pm | San Jose BioCenter

Speakers
Stacey Feld, Director, Physic Ventures
Andrew Williamson, Director, Physic Ventures

Physic Ventures, based in San Francisco, provides capital and support to entrepreneurs focused on building exceptional science-based, consumer-directed health and sustainable living companies. Our strategy is to capitalize on major economic, social and political trends shaping the landscape of personal and planetary health, including the rapid migration toward a consumer-driven, prevention-oriented "self-care" paradigm.

At this event companies will hear a presentation by Physic Ventures to hear what they are looking for in a company. Then the attendees will have a private meeting with one of the Directors - Stacey Feld or Andrew Williamson. The “Meet with…” Series provides greater access to a pipeline of emerging companies for Foundations, Angels, Investors, Governmental Agencies, Big Pharmas, and others who have partnering and/or financing opportunities. To apply, please send executive summary to [email protected]

Meet With... Takeda Research Investment, Inc.
July 21, 2009 | 9:00 am - 4:00 pm | San Jose BioCenter

Speaker
Juan Harrison, Vice President, Takeda Research Investment, Inc.

Takeda Research Investment, Inc. (TRI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a world-class pharmaceutical company and the largest in Japan. A wholly-owned subsidiary of Takeda America Holdings, Inc., TRI started operations in 2002. Our aim is to encourage and support therapeutic innovation in biopharmaceutical companies and academic centers of excellence, through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company.

Financial Darwinism: Which Companies are the Fittest
September 3, 2009| 3pm-6:30pm | Orrick | Menlo Park, CA
Modern evolution theory suggests only the fittest will survive; in the business world, we know this to be fact.  Find out what it takes to prepare your company for survival. Join this panel to hear survival tips from VC investors, and what they look for in a investment.

Speakers
Peter McWilliams, Principal, Sanderling Ventures
Bob Ward, Principal, Kaiser Permanente Ventures
Anna Williamson, Business Development, Genentech Inc.
Doug Fisher, Principal, InterWest Partners
Greg Heibel, Partner, Orrick

Industry Events